dc.contributor
Institut Català de la Salut
dc.contributor
[Coles AJ, Jones JL] Department of Clinical Neuroscience, School of Medicine, University of Cambridge, Cambridge, UK. [Vermersch P] Univ. Lille, INSERM UMR-S1172—Lille Neuroscience et Cognition, CHU Lille, FHU Precise, Lille, France. [Traboulsee A] The University of British Columbia, Vancouver, BC, Canada. [Bass AD] Neurology Center of San Antonio, San Antonio, TX, USA. [Boster A] Boster MS Center, Columbus, OH, USA. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Jones, Joanne
dc.contributor.author
Vermersch, Patrick
dc.contributor.author
Bass, Ann D
dc.contributor.author
Boster, Aaron
dc.contributor.author
Montalban Gairín, Xavier
dc.contributor.author
Coles, Alasdair
dc.contributor.author
Traboulsee, Anthony
dc.date.accessioned
2025-10-24T10:39:26Z
dc.date.available
2025-10-24T10:39:26Z
dc.date.issued
2022-06-09T07:23:29Z
dc.date.issued
2022-06-09T07:23:29Z
dc.date.issued
2022-04-01
dc.identifier
Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, et al. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Mult Scler J. 2022 Apr 1;28(5):842–846.
dc.identifier
https://hdl.handle.net/11351/7650
dc.identifier
10.1177/13524585211061335
dc.identifier
000729548200001
dc.identifier.uri
http://hdl.handle.net/11351/7650
dc.description.abstract
Alemtuzumab; Product surveillance; Risk assessment
dc.description.abstract
Alemtuzumab; Vigilancia de productos; Evaluación de riesgos
dc.description.abstract
Alemtuzumab; Vigilància de productes; Avaluació de riscos
dc.description.abstract
Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab? In the extended phase 2/3 trials, 34/96 (35.4%) patients with and 395/1120 (35.3%) without preexisting autoimmunity developed non-MS autoimmunity. Thyroid autoimmunity after alemtuzumab courses 1 or 2 did not increase subsequent non-thyroid autoimmune adverse events. Therefore, autoimmune disease before or after alemtuzumab treatment does not predict autoimmunity after further courses, so should not preclude adequate alemtuzumab dosing to control MS. Finally, post-marketing safety data contribute toward a full record of the alemtuzumab benefit/risk profile for the MS field.
dc.description.abstract
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The CAMMS223 and CARE-MS studies, and their extensions, were supported by Sanofi and Bayer Healthcare Pharmaceuticals. Editorial and writing assistance was supported by Sanofi.
dc.format
application/pdf
dc.publisher
SAGE Publications
dc.relation
Multiple Sclerosis Journal;28(5)
dc.relation
https://doi.org/10.1177/13524585211061335
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Esclerosi múltiple - Tractament
dc.subject
Avaluació de resultats (Assistència sanitària)
dc.subject
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
PHENOMENA AND PROCESSES::Immune System Phenomena::Immunity::Autoimmunity
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::inmunidad::autoinmunidad
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
dc.title
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
